Mira Pharmaceuticals reports positive 7-day rat, dog tox studies for oral pain drug MIRA-55 ahead of IND push
MIRA•Early animal safety results support continued development of MIRA-55
Mira Pharmaceuticals reported positive early-stage animal safety results for its oral, non-opioid inflammatory pain candidate MIRA-55.
- Results have already been presented, positioning the program to select doses for the next IND-enabling toxicology studies.
- Studies indicated tolerability across species, supporting continued development toward first-in-human testing.
- IND submission is targeted for Q1 2027, pending completion of remaining preclinical requirements.
